SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-19-061794
Filing Date
2019-03-04
Accepted
2019-03-04 09:20:10
Documents
10
Effectiveness Date
2019-03-04

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d701876d8k.htm DEFA14A 51806
2 EX-2.1 d701876dex21.htm EX-2.1 502422
3 EX-99.1 d701876dex991.htm EX-99.1 56970
4 EX-99.2 d701876dex992.htm EX-99.2 71871
5 EX-99.3 d701876dex993.htm EX-99.3 199893
6 EX-99.4 d701876dex994.htm EX-99.4 18293
7 GRAPHIC g701876dsp10a.jpg GRAPHIC 1926
8 GRAPHIC g701876dsp67.jpg GRAPHIC 2912
9 GRAPHIC g701876g0304105029453.jpg GRAPHIC 1419
10 GRAPHIC g701876sig.jpg GRAPHIC 3455
  Complete submission text file 0001193125-19-061794.txt   916404
Mailing Address C/O NIGHTSTAR, INC. 203 CRESCENT STREET, SUITE 303 WALTHAM MA 02453
Business Address C/O NIGHTSTAR, INC. 203 CRESCENT STREET, SUITE 303 WALTHAM MA 02453 781-778-7553
Nightstar Therapeutics plc (Filer) CIK: 0001711675 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38217 | Film No.: 19652120
SIC: 2836 Biological Products, (No Diagnostic Substances)